Family Health Ministries, Durham, North Carolina, United States of America ; Duke Global Health Institute, Durham, North Carolina, United States of America.
PLoS One. 2013 Oct 3;8(10):e76110. doi: 10.1371/journal.pone.0076110. eCollection 2013.
There have been no published studies of carcinogenic human papillomavirus (HPV)--the necessary cause of cervical cancer--in Haiti, a nation that has one of the greatest burdens of cervical cancer globally.
Characterize prevalence of carcinogenic HPV and the prevalence of individual carcinogenic HPV genotypes in women with cervical precancer or cancer, cervical intraepithelial neoplasia grade 2 (CIN2) or more severe (CIN2+).
Women (n=9,769; aged 25-60 years) were screened for carcinogenic HPV by Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD). Carcinogenic HPV positives underwent colposcopy and visible lesions were biopsied. A subset of carcinogenic HPV positives was tested for individual HPV genotypes using a GP5+/6+ assay.
The prevalence of carcinogenic HPV was 19.0% (95% confidence interval: 18.4%-19.9%) and decreased with increasing age (ptrend < 0.001). Women with 3 or more sexual partners and who started sex before the age of 18 years had twice the age-adjusted prevalence of carcinogenic HPV of women with one partner and who started sex after the age of 21 (24.3% vs. 12.9%, respectively). HPV16 and HPV35 were the most common HPV genotypes detected in CIN2+ and more common in women with CIN2+ than those without CIN2+. HPV16 and/or HPV18 were detected in 21.0% of CIN2 (n = 42), 46.2% of CIN3 (n = 52), and 80% of cancers (n = 5).
The prevalence of carcinogenic HPV in Haiti was much greater than the prevalence in other Latin American countries. High carcinogenic HPV prevalence and a lack of cervical cancer screening may explain the high burden of cervical cancer in Haiti.
海地是全球宫颈癌负担最重的国家之一,但目前尚无关于致癌型人乳头瘤病毒(HPV)——宫颈癌的必要病因——的发表研究。
描述宫颈癌前病变或癌症、宫颈上皮内瘤变 2 级(CIN2)及更高级别病变(CIN2+)患者中致癌型 HPV 的流行率及个体致癌型 HPV 基因型的流行率。
采用凯杰(Qiagen)公司的 Hybrid Capture 2(HC2)对 9769 名年龄在 25-60 岁的女性进行致癌型 HPV 筛查。HPV 阳性者行阴道镜检查,肉眼可见病变行活检。对部分 HPV 阳性者采用 GP5+/6+检测法进行个体 HPV 基因型检测。
致癌型 HPV 的流行率为 19.0%(95%置信区间:18.4%-19.9%),且随年龄增加而降低(ptrend<0.001)。性伴侣≥3 个和初次性行为年龄<18 岁的女性,其致癌型 HPV 的年龄校正流行率是性伴侣 1 个且初次性行为年龄≥21 岁女性的 2 倍(分别为 24.3%和 12.9%)。CIN2+患者中最常见的 HPV 基因型是 HPV16 和 HPV35,且其流行率高于非 CIN2+患者。CIN2 患者中 21.0%(42 例)、CIN3 患者中 46.2%(52 例)和癌症患者中 80%(5 例)检出 HPV16 和(或)HPV18。
海地的致癌型 HPV 流行率远高于其他拉丁美洲国家。高致癌型 HPV 流行率和缺乏宫颈癌筛查可能是海地宫颈癌负担重的原因。